Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The investigators' goal is to develop neuroimaging biomarkers to predict response to
treatment with methylphenidate, which then can be used in the development of novel
pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall
objective of this study is to measure the changes in task-related neural activity related to
symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by
magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will
be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants
will complete neuropsychological testing along with fMRI and MRS scans after a single dose of
each treatment.